Altimmune announces first quarter 2024 financial results and provides a business update

Enrollment ongoing in impact phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (mash), with top line results expected in q1 2025
ALT Ratings Summary
ALT Quant Ranking